{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=31", "query": { "intervention": "Cell Therapy", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 12464, "total_pages": 1247, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=32&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cell+Therapy&page=30&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T03:06:05.531Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006093", "title": "EMD 121974 in Treating Patients With Progressive or Recurrent Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New Approaches to Brain Tumor Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-09", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006093" }, { "nct_id": "NCT02898116", "title": "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Carcinoma", "NSCLC" ], "interventions": [ { "name": "Ensartinib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-05-10", "completion_date": "2017-08-04", "has_results": true, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02898116" }, { "nct_id": "NCT03348631", "title": "Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Tazemetostat", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2019-05-01", "completion_date": "2027-02-12", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 581, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 369 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03348631" }, { "nct_id": "NCT00003502", "title": "Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Contiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage IV Mantle Cell Lymphoma", "Recurrent Mantle Cell Lymphoma" ], "interventions": [ { "name": "antineoplaston A10", "type": "DRUG" }, { "name": "antineoplaston AS2-1", "type": "DRUG" }, { "name": "alternative product therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "biologically based therapies", "type": "PROCEDURE" }, { "name": "cancer prevention intervention", "type": "PROCEDURE" }, { "name": "complementary and alternative therapy", "type": "PROCEDURE" }, { "name": "differentiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Burzynski Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003502" }, { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT00265837", "title": "Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "graft versus host disease prophylaxis/therapy", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "65 Years", "sex": "ALL", "summary": "Up to 65 Years" }, "enrollment_count": 72, "start_date": "2002-12", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265837" }, { "nct_id": "NCT00004239", "title": "506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Compound 506U78", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "1999-12", "completion_date": "2002-01", "has_results": false, "last_update_posted_date": "2016-07-04", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 3, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Winston-Salem, North Carolina", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004239" }, { "nct_id": "NCT01535053", "title": "Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Choriocarcinoma", "FIGO Stage I Gestational Trophoblastic Tumor", "FIGO Stage II Gestational Trophoblastic Tumor", "FIGO Stage III Gestational Trophoblastic Tumor", "Hydatidiform Mole" ], "interventions": [ { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 57, "start_date": "2012-06-18", "completion_date": "2020-07-17", "has_results": true, "last_update_posted_date": "2022-08-12", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 267, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Burbank, California + 181 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01535053" }, { "nct_id": "NCT07393867", "title": "Androgen-responsive POSLUMA-guided Intra-prostatic Boost", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intermediate Risk Prostate Cancer", "High Risk Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "PSMA PET/CT", "type": "DIAGNOSTIC_TEST" }, { "name": "Androgen Deprivation Therapy (ADT) +/- bicalutamide", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost", "type": "RADIATION" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG", "RADIATION" ], "sponsor": "Martin T. King, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 23, "start_date": "2026-04-29", "completion_date": "2027-12-15", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Milford", "state": "Massachusetts" }, { "city": "Weymouth", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07393867" }, { "nct_id": "NCT02793544", "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Lymphocytic Leukemia (CLL)", "Chemotherapy-sensitive Lymphoma", "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma", "Acute Myelogenous Leukemia (AML)", "Acute Biphenotypic Leukemia (ABL)", "Acute Undifferentiated Leukemia (AUL)" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy on Day -1", "type": "RADIATION" }, { "name": "Infusion of non-T-cell depleted bone marrow on Day 0", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1", "type": "RADIATION" }, { "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -6 and -5", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -2 and -1", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -5 and -4", "type": "DRUG" }, { "name": "Post-HCT Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2016-12", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-10-26T03:06:05.531Z", "location_count": 11, "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793544" } ] }